Literature DB >> 16219609

Aprepitant (EMEND): the role of substance P in nausea and vomiting.

Eric Prommer1.   

Abstract

Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16219609

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN： 1536-0288


  9 in total

1.  The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways.

Authors:  Hossein Javid; Jahanbakhsh Asadi; Farnaz Zahedi Avval; Amir R Afshari; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2020-02-18       Impact factor: 2.316

Review 2.  Pharmacokinetic evaluation of fosaprepitant dimeglumine.

Authors:  Francheska Colon-Gonzalez; Walter K Kraft
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

3.  Rare variants in drug target genes contributing to complex diseases, phenome-wide.

Authors:  Shefali Setia Verma; Navya Josyula; Anurag Verma; Xinyuan Zhang; Yogasudha Veturi; Frederick E Dewey; Dustin N Hartzel; Daniel R Lavage; Joe Leader; Marylyn D Ritchie; Sarah A Pendergrass
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

Review 4.  Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury.

Authors:  Emma Thornton; Jenna M Ziebell; Anna V Leonard; Robert Vink
Journal:  Molecules       Date:  2010-09-20       Impact factor: 4.411

Review 5.  Functional, Diagnostic and Therapeutic Aspects of Gastrointestinal Hormones.

Authors:  Monjur Ahmed; Sarah Ahmed
Journal:  Gastroenterology Res       Date:  2019-10-04

6.  The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells.

Authors:  Faranak Korfi; Hossein Javid; Reza Assaran Darban; Seyed Isaac Hashemy
Journal:  Biochem Res Int       Date:  2021-04-21

7.  Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial.

Authors:  Sergio Bergese; Adolfo Viloria; Alberto Uribe; Alejandra Antor; Soledad Fernandez
Journal:  Trials       Date:  2012-08-03       Impact factor: 2.279

8.  Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Luigi Celio; Francesca Ricchini; Filippo De Braud
Journal:  Patient Prefer Adherence       Date:  2013-05-07       Impact factor: 2.711

Review 9.  The role of substance P in epilepsy and seizure disorders.

Authors:  Xue Feng Wang; Tong Tong Ge; Jie Fan; Wei Yang; Ran Ji Cui
Journal:  Oncotarget       Date:  2017-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.